## Brisa S Fernandes

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4214227/publications.pdf

Version: 2024-02-01

89 papers 7,811 citations

43 h-index 79 g-index

94 all docs 94 docs citations

times ranked

94

10696 citing authors

#	Article	IF	CITATIONS
1	Peripheral cytokine and chemokine alterations in depression: a metaâ€analysis of 82 studies. Acta Psychiatrica Scandinavica, 2017, 135, 373-387.	4.5	946
2	Relationship between depression and frailty in older adults: A systematic review and meta-analysis. Ageing Research Reviews, 2017, 36, 78-87.	10.9	479
3	Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder. Journal of Affective Disorders, 2009, 116, 214-217.	4.1	376
4	Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: A systematic review and meta-regression analysis. Journal of Psychiatric Research, 2011, 45, 995-1004.	3.1	349
5	The new field of â€~precision psychiatry'. BMC Medicine, 2017, 15, 80.	5.5	347
6	Peripheral Alterations in Cytokine and Chemokine Levels After Antidepressant Drug Treatment for Major Depressive Disorder: Systematic Review and Meta-Analysis. Molecular Neurobiology, 2018, 55, 4195-4206.	4.0	279
7	C-reactive protein is increased in schizophrenia but is not altered by antipsychotics: meta-analysis and implications. Molecular Psychiatry, 2016, 21, 554-564.	7.9	254
8	Peripheral brain-derived neurotrophic factor (BDNF) as a biomarker in bipolar disorder: a meta-analysis of 52 studies. BMC Medicine, 2015, 13, 289.	5.5	233
9	Early Intervention in Bipolar Disorder. American Journal of Psychiatry, 2018, 175, 411-426.	7.2	218
10	Depression in cancer: The many biobehavioral pathways driving tumor progression. Cancer Treatment Reviews, 2017, 52, 58-70.	7.7	204
11	Peripheral brain-derived neurotrophic factor in schizophrenia and the role of antipsychotics: meta-analysis and implications. Molecular Psychiatry, 2015, 20, 1108-1119.	7.9	200
12	Biomarkers in bipolar disorder: A positional paper from the International Society for Bipolar Disorders Biomarkers Task Force. Australian and New Zealand Journal of Psychiatry, 2013, 47, 321-332.	2.3	193
13	Cognitive remission: a novel objective for the treatment of major depression?. BMC Medicine, 2016, 14, 9.	5.5	177
14	C-reactive protein concentrations across the mood spectrum in bipolar disorder: a systematic review and meta-analysis. Lancet Psychiatry,the, 2016, 3, 1147-1156.	7.4	169
15	The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: An open label trial. Journal of Affective Disorders, 2011, 135, 389-394.	4.1	162
16	Mapping risk factors for depression across the lifespan: An umbrella review of evidence from meta-analyses and Mendelian randomization studies. Journal of Psychiatric Research, 2018, 103, 189-207.	3.1	162
17	Oxidative stress and frailty: A systematic review and synthesis of the best evidence. Maturitas, 2017, 99, 66-72.	2.4	160
18	Staging in bipolar disorder: from theoretical framework to clinical utility. World Psychiatry, 2017, 16, 236-244.	10.4	160

#	Article	IF	CITATIONS
19	Decreased peripheral brain-derived neurotrophic factor levels are a biomarker of disease activity in major psychiatric disorders: a comparative meta-analysis. Molecular Psychiatry, 2014, 19, 750-751.	7.9	135
20	The kynurenine pathway in major depressive disorder, bipolar disorder, and schizophrenia: a meta-analysis of 101 studies. Molecular Psychiatry, 2021, 26, 4158-4178.	7.9	135
21	Serum levels of IL-6, IL-10 and TNF-α in patients with bipolar disorder and schizophrenia: differences in pro- and anti-inflammatory balance. Revista Brasileira De Psiquiatria, 2011, 33, 268-274.	1.7	131
22	Use of statins and the risk of dementia and mild cognitive impairment: A systematic review and meta-analysis. Scientific Reports, 2018, 8, 5804.	3.3	118
23	Serum brain-derived neurotrophic factor in bipolar and unipolar depression: A potential adjunctive tool for differential diagnosis. Journal of Psychiatric Research, 2009, 43, 1200-1204.	3.1	111
24	Improvement of Negative and Positive Symptoms in Treatment-Refractory Schizophrenia. Journal of Clinical Psychiatry, 2009, 70, 1416-1423.	2.2	108
25	Statins for the treatment of depression: A meta-analysis of randomized, double-blind, placebo-controlled trials. Journal of Affective Disorders, 2016, 200, 235-242.	4.1	104
26	Evidence-based umbrella review of 162 peripheral biomarkers for major mental disorders. Translational Psychiatry, 2020, 10, 152.	4.8	102
27	Serum levels of IL-6, IL-10 and TNF-α in patients with bipolar disorder and schizophrenia: differences in pro- and anti-inflammatory balance. Revista Brasileira De Psiquiatria, 2011, 33, 268-274.	1.7	102
28	Decreased brain-derived neurotrophic factor in medicated and drug-free bipolar patients. Journal of Psychiatric Research, 2009, 43, 1171-1174.	3.1	101
29	The renin–angiotensin system: a possible new target for depression. BMC Medicine, 2017, 15, 144.	5.5	98
30	<em>N</em> -Acetylcysteine in Depressive Symptoms and Functionality. Journal of Clinical Psychiatry, 2016, 77, e457-e466.	2.2	93
31	Leaky brain in neurological and psychiatric disorders: Drivers and consequences. Australian and New Zealand Journal of Psychiatry, 2018, 52, 924-948.	2.3	90
32	The effect of N-acetylcysteine (NAC) on human cognition – A systematic review. Neuroscience and Biobehavioral Reviews, 2017, 78, 44-56.	6.1	82
33	Maintenance N-acetyl cysteine treatment for bipolar disorder: A double-blind randomized placebo controlled trial. BMC Medicine, 2012, 10, 91.	5.5	81
34	T helper 17 cells may drive neuroprogression in major depressive disorder: Proposal of an integrative model. Neuroscience and Biobehavioral Reviews, 2016, 64, 83-100.	6.1	74
35	Serum brain-derived neurotrophic factor (BDNF) is not associated with response to electroconvulsive therapy (ECT): A pilot study in drug resistant depressed patients. Neuroscience Letters, 2009, 453, 195-198.	2.1	72
36	Serum triglycerides, but not cholesterol or leptin, are decreased in suicide attempters with mood disorders. Journal of Affective Disorders, 2015, 172, 403-409.	4.1	71

3

#	Article	IF	CITATIONS
37	Peripheral vascular endothelial growth factor as a novel depression biomarker: A meta-analysis. Psychoneuroendocrinology, 2015, 62, 18-26.	2.7	70
38	The Placebo and Nocebo Phenomena: Their Clinical Management and Impact on Treatment Outcomes. Clinical Therapeutics, 2017, 39, 477-486.	2.5	69
39	The impact of methylphenidate on seizure frequency and severity in children with attentionâ€deficitâ€"hyperactivity disorder and difficultâ€toâ€treat epilepsies. Developmental Medicine and Child Neurology, 2013, 55, 654-660.	2.1	59
40	Treatment of neurocognitive symptoms in unipolar depression: A systematic review and future perspectives. Journal of Affective Disorders, 2017, 221, 205-221.	4.1	56
41	Bias in emerging biomarkers for bipolar disorder. Psychological Medicine, 2016, 46, 2287-2297.	4.5	50
42	Effects of Depression and Serotonergic Antidepressants on Bone: Mechanisms and Implications for the Treatment of Depression. Drugs and Aging, 2016, 33, 21-25.	2.7	50
43	Bias in Peripheral Depression Biomarkers. Psychotherapy and Psychosomatics, 2016, 85, 81-90.	8.8	46
44	Innate Immune Cells and C-Reactive Protein in Acute First-Episode Psychosis and Schizophrenia: Relationship to Psychopathology and Treatment. Schizophrenia Bulletin, 2020, 46, 363-373.	4.3	46
45	Increased neurotrophin-3 in drug-free subjects with bipolar disorder during manic and depressive episodes. Journal of Psychiatric Research, 2010, 44, 561-565.	3.1	44
46	Homocysteine as a peripheral biomarker in bipolar disorder: A meta-analysis. European Psychiatry, 2017, 43, 81-91.	0.2	33
47	Precision psychiatry with immunological and cognitive biomarkers: a multi-domain prediction for the diagnosis of bipolar disorder or schizophrenia using machine learning. Translational Psychiatry, 2020, 10, 162.	4.8	33
48	Leptin in bipolar disorder: A systematic review and meta-analysis. European Psychiatry, 2016, 35, 1-7.	0.2	32
49	Blockade of the angiotensin system improves mental health domain of quality of life: A meta-analysis of randomized clinical trials. Australian and New Zealand Journal of Psychiatry, 2018, 52, 24-38.	2.3	31
50	The concept of staging in bipolar disorder: the role of BDNF and TNF-alpha as biomarkers. Acta Neuropsychiatrica, 2009, 21, 272-274.	2.1	29
51	Insulin resistance in depression: A large meta-analysis of metabolic parameters and variation. Neuroscience and Biobehavioral Reviews, 2022, 139, 104758.	6.1	28
52	Guidelines for the standardized collection of blood-based biomarkers in psychiatry: Steps for laboratory validity – a consensus of the Biomarkers Task Force from the WFSBP. World Journal of Biological Psychiatry, 2019, 20, 340-351.	2.6	20
53	Angiotensin Converting Enzyme Inhibitors and Risk of Mood Disorders. Psychotherapy and Psychosomatics, 2016, 85, 250-252.	8.8	19
54	Imaging genetics paradigms in depression research: Systematic review and meta-analysis. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 86, 102-113.	4.8	19

#	Article	IF	Citations
55	Glucose homeostasis in major depression and schizophrenia: a comparison among drug-na $\tilde{A}^-$ ve first-episode patients. European Archives of Psychiatry and Clinical Neuroscience, 2019, 269, 373-377.	3.2	19
56	Minimum 2â€year follow up of sex reassignment surgery in Brazilian maleâ€ŧoâ€female transsexuals. Psychiatry and Clinical Neurosciences, 2012, 66, 371-372.	1.8	18
57	Statins: Neurobiological underpinnings and mechanisms in mood disorders. Neuroscience and Biobehavioral Reviews, 2021, 128, 693-708.	6.1	15
58	Charting the proteome landscape in major psychiatric disorders: From biomarkers to biological pathways towards drug discovery. European Neuropsychopharmacology, 2022, 61, 43-59.	0.7	15
59	Staging in bipolar disorder: one step closer to precision psychiatry. Revista Brasileira De Psiquiatria, 2017, 39, 88-89.	1.7	14
60	Are remitted affective disorders and familial risk of affective disorders associated with metabolic syndrome, inflammation and oxidative stress? – a monozygotic twin study. Psychological Medicine, 2020, 50, 1736-1745.	4.5	12
61	Prescription fill patterns for benzodiazepine and opioid drugs during the COVID-19 pandemic in the United States. Drug and Alcohol Dependence, 2021, 229, 109176.	3.2	12
62	Improvement of schizophrenia with electroconvulsive therapy and serum brainâ€derived neurotrophic factor levels: Lack of association in a pilot study. Psychiatry and Clinical Neurosciences, 2010, 64, 663-665.	1.8	11
63	Future Directions for Pharmacotherapies for Treatment-resistant Bipolar Disorder. Current Neuropharmacology, 2015, 13, 656-662.	2.9	11
64	Editorial: Back to the Future: On the Road Towards Precision Psychiatry. Frontiers in Psychiatry, 2020, 11, 112.	2.6	9
65	Lack of Association Between Serum Brain-Derived Neurotrophic Factor Levels and Improvement of Schizophrenia Symptoms in a Double-Blind, Randomized, Placebo-Controlled Trial of Memantine as Adjunctive Therapy to Clozapine. Journal of Clinical Psychiatry, 2010, 71, 91-92.	2.2	9
66	Aspirin and incident depressive symptoms: A longitudinal cohort study over 8Âyears. International Journal of Geriatric Psychiatry, 2018, 33, e193-e198.	2.7	8
67	Distinct effect of prenatal and postnatal brain expression across 20 brain disorders and anthropometric social traits: a systematic study of spatiotemporal modularity. Briefings in Bioinformatics, 2021, 22, .	6.5	8
68	Treatment-resistant bipolar depression: concepts and challenges for novel interventions. Revista Brasileira De Psiquiatria, 2022, 44, 178-186.	1.7	7
69	Feasibility of Treating Swine Manure in an Anaerobic Sequencing Batch Biofilm Reactor With Mechanical Stirring. Applied Biochemistry and Biotechnology, 2005, 120, 109-120.	2.9	6
70	Reduced serum non-enzymatic antioxidant defense and increased lipid peroxidation in schizophrenic patients on a hypocaloric diet. Neuroscience Letters, 2012, 512, 43-47.	2.1	6
71	Affective temperaments and emotional traits are associated with a positive screening for premenstrual dysphoric disorder. Comprehensive Psychiatry, 2016, 71, 33-38.	3.1	5
72	White matter microstructure associated with anhedonia among individuals with bipolar disorders and high-risk for bipolar disorders. Journal of Affective Disorders, 2022, 300, 91-98.	4.1	4

#	Article	IF	Citations
73	338. Enabling Precision Psychiatry through â€~omics': From Biomarkers to Biological Pathways. Biological Psychiatry, 2017, 81, S138-S139.	1.3	3
74	Validity of the Portuguese version of the Bipolar Depression Rating Scale. Acta Neuropsychiatrica, 2010, 22, 100-101.	2.1	2
75	Hypersalivation Associated with Olanzapine and Valproate Combination: A Case Report. CNS Spectrums, 2011, 16, 83-83.	1.2	1
76	Mindfulness-based stress reduction for fibromyalgia: A step closer to precision psychiatry?. Brain, Behavior, and Immunity, 2019, 81, 8-9.	4.1	1
77	C-Reactive Protein and the Uncinate Fasciculus in Anhedonia and Depression. Biological Psychiatry, 2021, 89, S272.	1.3	1
78	The Kynurenine Pathway in Major Depressive Disorder, Bipolar Disorder, and Schizophrenia: A Large Meta-Analysis. Biological Psychiatry, 2021, 89, S377.	1.3	1
79	Fostering precision psychiatry through bioinformatics. Revista Brasileira De Psiquiatria, 2021, , .	1.7	1
80	980. Insulin is a State Biomarker in Major Depressive Disorder: A Systematic Review and Meta-Analysis. Biological Psychiatry, 2017, 81, S396-S397.	1.3	0
81	Applying biomarkers in psychiatry: Paving the way towards precision psychiatry. Psychoneuroendocrinology, 2019, 107, 44.	2.7	O
82	P.4.08 Metabolic syndrome, inflammation and oxidative stress as potential risk factors for affective disorders – a twin study. European Neuropsychopharmacology, 2019, 29, S706-S707.	0.7	0
83	P.757 Antidepressant treatment decreases IL-6, IL-10 and serum cortisol in major depressive disorder: a meta-analysis of randomized controlled trials. European Neuropsychopharmacology, 2020, 40, S428-S429.	0.7	0
84	Lower Reward Responsiveness is Associated With Lifetime Suicide Attempt in Children and Adolescents With Bipolar Disorders. Biological Psychiatry, 2021, 89, S242.	1.3	0
85	The Greater Houston Area Bipolar Registry—Clinical and Neurobiological Trajectories of Children and Adolescents With Bipolar Disorders and High-Risk Unaffected Offspring. Frontiers in Psychiatry, 2021, 12, 671840.	2.6	0
86	The treatment of bipolar disorder in the era of precision psychiatry: Challenges and opportunities. , $2021, , 405-415.$		0
87	Evaluation of the treadmill stress testing for risk stratification after acute myocardial infarction. Arquivos Brasileiros De Cardiologia, 1999, 73, 532-536.	0.8	0
88	Progressing Towards Precision Psychiatry., 2019,, 520-528.		0
89	Pharmacogenomics in bipolar disorder: towards precision psychiatry and personalized treatment., 2022,, 483-496.		0